Division of Pharmacy, School of Pharmacy, University of Oslo, Oslo, Norway.
BJOG. 2013 Jul;120(8):948-59. doi: 10.1111/1471-0528.12192. Epub 2013 Mar 14.
To investigate the individual effects of ibuprofen, diclofenac, naproxen, and piroxicam on pregnancy outcome.
Cohort study.
Norwegian population.
A total of 90 417 women and singleton child pairs.
The Norwegian Mother and Child Cohort Study and Medical Birth Registry of Norway data sets were used.
Infant survival, congenital malformations, structural heart defects, neonatal complications, haemorrhage during pregnancy and postpartum, asthma at age of 18 months.
One or more of the four nonsteroidal anti-inflammatory drugs (NSAIDs) were used by 6511 pregnant women (7.2%). No effect on rates of infant survival, congenital malformation, or structural heart defects was found. The use of ibuprofen in the second trimester was significantly associated with low birthweight (adjusted OR 1.7, 95% CI 1.3-2.3), and ibuprofen use in the second and third trimesters was significantly associated with asthma in 18-month-old children (adjusted OR 1.5, 95% CI 1.2-1.9; adjusted OR 1.5, 95% CI 1.1-2.1). The use of diclofenac in the second trimester was significantly associated with low birthweight (adjusted OR 3.1, 95% CI 1.1-9.0), whereas diclofenac use in the third trimester was significantly associated with maternal vaginal bleeding (adjusted OR 1.8, 95% CI 1.1-3.0). No associations with other neonatal complications were found.
The lack of associations with congenital malformations is reassuring. The significant association between diclofenac and ibuprofen use late in pregnancy, and maternal bleeding and asthma in the child, respectively, is consistent with their pharmacological effects. The increased risk of low birthweight may partly have been caused by underlying inflammatory conditions, and was reassuringly similar to the expected baseline risk of low birthweight.
研究布洛芬、双氯芬酸、萘普生和吡罗昔康对妊娠结局的个体影响。
队列研究。
挪威人群。
共 90417 名妇女和单胎儿童对。
使用挪威母婴队列研究和挪威医学出生登记处数据集。
婴儿存活率、先天性畸形、结构性心脏缺陷、新生儿并发症、妊娠和产后出血、18 个月时哮喘。
共有 6511 名孕妇(7.2%)使用了一种或多种非甾体抗炎药(NSAIDs)。未发现婴儿存活率、先天性畸形或结构性心脏缺陷发生率的变化。在妊娠中期使用布洛芬与低出生体重显著相关(调整后的比值比 1.7,95%置信区间 1.3-2.3),在妊娠中期和妊娠晚期使用布洛芬与 18 个月大的儿童哮喘显著相关(调整后的比值比 1.5,95%置信区间 1.2-1.9;调整后的比值比 1.5,95%置信区间 1.1-2.1)。在妊娠中期使用双氯芬酸与低出生体重显著相关(调整后的比值比 3.1,95%置信区间 1.1-9.0),而在妊娠晚期使用双氯芬酸与母亲阴道出血显著相关(调整后的比值比 1.8,95%置信区间 1.1-3.0)。未发现与其他新生儿并发症的关联。
未发现与先天性畸形的关联令人安心。在妊娠晚期使用双氯芬酸和布洛芬,以及儿童出血和哮喘分别与各自的药理学效应一致。低出生体重风险增加可能部分是由潜在的炎症情况引起的,这与低出生体重的预期基线风险相似,令人安心。